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Abstract 
The exquisite soft-tissue contrast of magnetic resonance imaging (MRI) has meant that the technique is 
having an increasing role in contouring the gross tumor volume (GTV) and organs at risk (OAR) in 
radiation therapy treatment planning systems (TPS). MRI-planning scans from diagnostic MRI scanners 
are currently incorporated into the planning process by being registered to CT data. The soft-tissue data 
from the MRI provides target outline guidance and the CT provides a solid geometric and electron density 
map for accurate dose calculation on the TPS computer. There is increasing interest in MRI machine 
placement in radiotherapy clinics as an adjunct to CT simulators. Most vendors now offer 70 cm bores 
with flat couch inserts and specialised RF coil designs. We would refer to these devices as MR-
simulators. There is also research into the future application of MR-simulators independent of CT and as 
in-room image-guidance devices. It is within the background of this increased interest in the utility of MRI 
in radiotherapy treatment planning that this paper is couched. The paper outlines publications that deal 
with standard MRI sequences used in current clinical practice. It then discusses the potential for using 
processed functional diffusion maps (fDM) derived from diffusion weighted image sequences in tracking 
tumor activity and tumor recurrence. Next, this paper reviews publications that describe the use of MRI in 
patient-management applications that may, in turn, be relevant to radiotherapy treatment planning. The 
review briefly discusses the concepts behind functional techniques such as dynamic contrast enhanced 
(DCE), diffusion-weighted (DW) MRI sequences and magnetic resonance spectroscopic imaging (MRSI). 
Significant applications of MR are discussed in terms of the following treatment sites: brain, head and 
neck, breast, lung, prostate and cervix. While not yet routine, the use of apparent diffusion coefficient 
(ADC) map analysis indicates an exciting future application for functional MRI. Although DW-MRI has not 
yet been routinely used in boost adaptive techniques, it is being assessed in cohort studies for sub-
volume boosting in prostate tumors. 
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The exquisite soft-tissue contrast of magnetic resonance imaging (MRI) has meant that the 
technique is having an increasing role in contouring the gross tumor volume (GTV) and organs 
at risk (OAR) in radiation therapy treatment planning systems (TPS). MRI-planning scans 
from diagnostic MRI scanners are currently incorporated into the planning process by being 
registered to CT data. The soft-tissue data from the MRI provides target outline guidance and 
the CT provides a solid geometric and electron density map for accurate dose calculation on 
the TPS computer. There is increasing interest in MRI machine placement in radiotherapy 
clinics as an adjunct to CT simulators. Most vendors now offer 70 cm bores with flat couch 
inserts and specialised RF coil designs. We would refer to these devices as MR-simulators. 
There is also research into the future application of MR-simulators independent of CT and as 
in-room image-guidance devices. It is within the background of this increased interest in the 
utility of MRI in radiotherapy treatment planning that this paper is couched. The paper outlines 
publications that deal with standard MRI sequences used in current clinical practice. It then 
discusses the potential for using processed functional diffusion maps (fDM) derived from 
diffusion weighted image sequences in tracking tumor activity and tumor recurrence. Next, 
this paper reviews publications that describe the use of MRI in patient-management applica-
tions that may, in turn, be relevant to radiotherapy treatment planning. The review briefly 
discusses the concepts behind functional techniques such as dynamic contrast enhanced 
(DCE), diffusion-weighted (DW) MRI sequences and magnetic resonance spectroscopic 
imaging (MRSI). Significant applications of MR are discussed in terms of the following treat-
ment sites: brain, head and neck, breast, lung, prostate and cervix. While not yet routine, the 
use of apparent diffusion coefficient (ADC) map analysis indicates an exciting future applica-
tion for functional MRI. Although DW-MRI has not yet been routinely used in boost adaptive 
techniques, it is being assessed in cohort studies for sub-volume boosting in prostate tumors. 
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considered for radiotherapy treatment planning purposes, and 
MRI sequences that show potential for future use. The use of 
MRI for radiation therapy treatment planning purposes has 
been considered across all clinical sites, with a more detailed 
review of the use of MRI in radiotherapy treatment planning 
for six clinical sites.
The first section of the results presents definitions and basic 
acquisition details for standard MRI sequences and imaging 
analysis methods used for, or considered for future use in, 
radiotherapy treatment planning. This provides a series of 
definitions that help with the discussion about sequences and 
analysis methods used in current MRI clinical practice and tri-
als, and includes concepts behind functional techniques such 
as dynamic contrast enhanced (DCE), diffusion-weighted 
(DW) MRI sequences and magnetic resonance spectroscopic 
imaging (MRSI).
The second section of the results discusses significant appli-
cations of MR in terms of the following treatment sites: brain, 
head and neck, breast, lung, prostate and cervix
Results
MRI sequences that have been considered for, or show poten-
tial for use in, radiotherapy treatment planning.
The most commonly used of the MR-visible nuclei is the 
hydrogen proton, which produces the strongest signal and is 
abundant in the body (primarily as water and fat). By chang-
ing the sequence parameters, MR images exploit the dif-
ferences in either “longitudinal” (T1) or “transverse” (T2) 
relaxation times of fat and water, producing large variations 
in contrast. 
In general, T1-weighted images are considered best for gross 
structural information (anatomy) and T2-weighted images 
for biological characteristics that may aid with pathology 
information. However, while extremely useful in many 
clinical applications and for diagnosis, neither of these imag-
ing methods provides sensitive or specific diagnosis and 
localization of either prostate or breast cancer (7, 8). This 
is because the tissue properties that give rise to differences 
in T1 and T2 are not closely related to the tissue structural 
features that define cancer. This shortcoming also applies 
to CT, which  reconstructs images from attenuation maps of 
x-ray projections, and hence essentially tracks  tissue-density 
changes (9, 10). There is, however, more potential to enhance 
MRI sequences, providing functional data to ascertain more 
clinical information such as tumor response than possible 
with CT. Some of the more exciting advanced techniques 
are outlined in this paper; many fall within the realm of so 
called “functional MRI”. Hence this term has been adopted 
(and used here) to describe any MRI technique capable 
Introduction
Developments in the field of radiotherapy such as intensity-
modulated radiation therapy (IMRT), volumetric modulated 
arc therapy (VMAT) and tomotherapy have provided the 
means to deliver highly conformal treatments offering the 
promise of improved sparing of normal tissue and escala-
tion of tumor dose. For these techniques to achieve their full 
potential there is an increasing need for anatomical and func-
tional imaging to be used at the planning stage, and ideally as 
a verification tool throughout radiotherapy to localise disease 
with a high level of accuracy. 
Computed tomography (CT) for imaging uses ionizing 
x-rays, and hence carries some stochastic increased risk in 
induction of a second primary malignancy from the ionizing 
radiation (1). While the risk of a single CT scan for plan-
ning is extremely small this risk is increased with repeat CT 
imaging in such scenarios as adaptive replanning in the radio-
therapy setting and with prolonged survival. Because MRI 
does not rely on ionizing radiation for imaging, there is no 
increased potential induction of secondary primary malig-
nancies associated with its use. 
Magnetic resonance imaging (MRI) is a non-ionising tech-
nique that uses a strong magnetic field to provide high- 
resolution anatomical information with excellent soft-tissue 
contrast. By using specific MRI techniques, functional infor-
mation such as tumor perfusion vascular permeability, extra-
cellular space tortuosity, metabolic status and hypoxia can 
also be obtained (2).
Development of MRI-Cobalt (ViewRay™) and MRI-linac 
prototypes is underway. It is envisaged these will enable 
MRI to be used for on-line image-guided radiation therapy 
(IGRT) (3, 4). The production of combined MRI-linacs is not 
trivial. Apart from the engineering challenges of RF pertur-
bation from the linac, there is the requirement to account for 
various electron-beam perturbation effects that affect dose at 
regions of air and lung-tissue interface (5). There has also 
been a feasibility study into the use of MRI in image guid-
ance for proton machines (6).
The focus of this review article is to provide some insight 
into the current role of MRI in radiation-therapy treatment 
planning. A future enhancement of this role is explored by 
examining clinical trials data of various cancer-treatment 
sites, sequences and analysis methods, such as functional 
MRI, that are currently applied to cancer management. 
Methods
Current literature has been reviewed using Medline and 
Google scholar to establish the MRI sequences that have been 
Technology in Cancer Research & Treatment 2013 April 24. Epub ahead of print
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of demonstrating information in addition to the anatomi-
cal images more routinely acquired (11-13). As a general 
description, functional MRI is used to define techniques that 
probe the status of the tumor itself. Some of the most relevant 
examples for radiotherapy are described briefly below.
Dynamic Contrast Enhanced MRI (DCE-MRI)
DCE-MRI is performed by sequential imaging following 
the injection of a suitable paramagnetic contrast agent (usu-
ally some gadolinium-based chelate). Fast gradient-echo 
sequences are used to image each slice as fast as possible with 
temporal resolutions of 2-10 s for 2D techniques and around 
30 s for 3D volumetric data. By using T2* images, data on 
tissue perfusion and blood volume can be extracted. By using 
sequences sensitive to the presence of contrast medium, T1 
methods can be used to evaluate the extravascular extracel-
lular space. Information on micro-vessel perfusion, perme-
ability and extracellular leakage space can also be obtained. 
The vast amount of imaging data produced by these meth-
ods may be viewed in a cine format either with or without 
pre-contrast subtraction. Regions-of-interest may be interro-
gated to produce enhancement-time curves with malignant 
tumors demonstrating a rapid wash-in and wash-out of con-
trast. Alternatively simple empirical measures such as peak 
enhancement or wash-in rate can be produced on a pixel-by-
pixel basis to provide parameter maps. More sophisticated 
models look to establish real physiological parameters from 
these datasets (14). DCE-MRI has been shown to have diag-
nostic value in various tumors, and correlates with the ther-
apy effect of standard chemotherapy and radiotherapy (2). 
Diffusion-Weighted MRI (DW-MRI)
DW-MRI scan sequences produce image contrast that 
depends on differences in tissue-water mobility. Two equally 
large, opposing gradient pulses in the diffusion sequence 
make the signal intensity dependent on the movement of 
water molecules. The first gradient pulse induces a phase shift 
of water molecules, followed by incomplete rephasing after 
the second gradient pulse, with the phase difference depend-
ing on the mobility of the water molecules. Incomplete 
rephasing of water molecules is less pronounced in hyper-
cellular tissue, characterized by less signal loss; rephasing 
is more pronounced in hypo-cellular tissue, which shows 
increased signal loss (15). The apparent diffusion coefficient 
(ADC), in units mm2/s, is the quantitative parameter used for 
the assessment of water diffusion through tissue. The term 
apparent reflects the concept that the measurement is subject 
to other factors not just water mobility. The sensitivity of the 
gradient scheme is defined by its “b-value”: by acquiring at 
least two images with different b values (usually b 5 0 and 
b 5 1000 s mm22) the ADC can be measured directly. The 
mean ADC values in the benign and malignant Head and 
Neck lesions have been observed as 1.51 3 1023 mm2/s and 
1.07 3 1023 mm2/s , respectively (16).
In biologic tissues, the movement of water molecules is 
restricted because their motion is modified and limited by 
interactions with cell membranes and macromolecules. 
There is an inverse correlation between the degree to which 
the motion of the water is restricted and the tissue cellularity. 
This inverse correlation also applies to the integrity of the 
cell membrane. Hence in a tumor with high cellularity, the 
motion of water molecules is more restricted. On the other 
hand, when a tumor has a high glandular component or has 
significant necrosis, there is less restriction of motion. In 
general, treatments inducing apoptosis (e.g., chemotherapy) 
result in increased ADC values due to cell swelling, tumor 
lysis and necrosis (2). 
In adenocarcinoma of the breast and prostate, for example, 
cancer development is characterized by the proliferation of 
epithelial cells and the loss of normal tissue architecture. 
An imaging method that generates contrast based on micro-
scopic tissue structural properties would be expected to 
provide cancer detection and staging, such that the contrast 
can be made to reflect the structures that define pathology. 
DW-MRI is an ideal candidate for this purpose because the 
free diffusion of water in tissue is known to be constrained 
by cellular structures and cell walls. This property has been 
used extensively in the study of neural tissue; the concept 
also been reported in cohort studies of head and neck cancer 
cases, but has had only limited clinical application to dis-
eases of glandular tissue such as breast and prostate (15). 
Pathologic prostate samples have also been examined at 
very high resolution (nominally 40 microns) in vitro in high 
field MR (16 T) and the lymphatic structures may be a con-
founding factor for ADC analysis at typical clinical voxel 
resolutions (17).
Diffusion-weighted imaging is probably the most useful 
new tool in tumor response, and cohort studies show its 
potential in providing evidence of tumor recurrence. One of 
the challenges with these sequences is that image-distortion 
artifacts are apparent in some of these sequences. Thus, 
defining regions of tumor burden may need some form of 
deformable registration to other MRI sequenced images or 
CT images if these potential volumes of recurrence are to 
be targeted with extra radiation treatment doses to selective 
intra-GTV regions by dose painting (18) or risk-adaptive 
boosting (19). 
Magnetic Resonance Spectroscopic Imaging (MRSI)
MR spectroscopy provides chemical information about tis-
sue metabolites, commonly using the MR visible nuclei 
of hydrogen (1H), phosphorus 31 (31P), fluorine 19 (19F) 
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or  carbon 13 (13C). Each specific nucleus exhibits a 
slight change in processional frequency that depends on 
its chemical environment. Specifically, variations in the 
electron shielding of different molecules alter the mag-
netic field and resonant frequency (the chemical shift). 
An MR spectrum is a kind of molecular fingerprint and 
may contain many peaks at specific frequencies (or chemi-
cal shifts), one for each chemically distinguishable site or 
group in a given metabolite or for specific sites in a variety 
of metabolites (2). 
The technique can be extended to MRSI, whereby spectra 
are acquired from multiple contiguous volumes (voxels), 
and peak areas or ratios are displayed with a color wash 
overlying the anatomy to provide a metabolic map. The 
small concentrations of metabolites necessitate the use of 
large voxels, and resolution can be as much as an order of 
magnitude poorer than in conventional imaging. Neverthe-
less, MRSI has been found to be useful in quantifying brain 
function and brain-related cancerous tumors where the rela-
tive amount of NAA to choline (related to cell turnover) is 
informative. In the prostate, the ratio of citrate to choline or 
choline1creatine is used in a similar manner. 
Lactate has been found to be indicative of hypoxia, and could 
therefore be used to mark out radio resistance. However 
Lactate can not currently be analysed accurately in vivo for 
prostate cancer. This biomarker can only currently be visu-
alized in prostate pathology samples ex-vivo at higher field 
strengths. Lactate has been successfully identified from lipids 
in head and neck and brain tumors with recent in vivo patient 
techniques (20).
Some degree of expertise is required to interpret the data, 
and the incorporation of this information into the planning 
system is still in its infancy. Another challenge when imag-
ing hypoxic regions is that hypoxic zones may be chronic 
or acute, and may change position over time. As this article 
does not focus on MRSI in great detail, the reader is guided 
to an excellent review on its use in brain, breast and prostate 
cancer (21).
Fast Sequences
MRI is an inherently slow technique compared to CT, requir-
ing numerous applications of imaging gradients to obtain 
the desired “k-space” data; the faster these gradients can 
be switched on and off, the faster the scan can be acquired. 
T2-weighted spin-echo sequences, with long repetition times 
(TR), are inherently slower than T1-weighted gradient echoes, 
which are often used as the basis for rapid imaging (22). Both 
types of sequences can be performed using segmented and 
partial k-space strategies to improve imaging speed. Single-
shot techniques, like eco planar imaging (EPI), apply all the 
gradient steps very rapidly in one single repetition. However, 
nerve stimulation provides a physiological limit to gradient 
speed and has necessitated other developments with the aim 
of faster imaging. In the last several years parallel imaging 
has become available on all commercial systems: it substi-
tutes some of the gradient steps with information provided 
from RF coil sensitivity profiles. All these techniques have 
combined to allow MRI to acquire sub-second images, and 
have opened the technique up to a number of challenging 
areas. These fast sequences may be critical to future IGRT 
applications of MRI.
Hyperpolarization
The sensitivity of MRI and MRSI can be increased 1,000 
to 10,000 times using hyperpolarization, whereby a sample 
containing nuclei that had their spin population temporar-
ily driven to a very high degree of polarization is introduced 
into the body. Procedures to probe pathological defects have 
been optimized for two noble-gas isotopes that can be inhaled 
into the human lung: helium 3 (3He) and xenon 129 (129Xe). 
An optical (laser) pumping technique is used to hyperpolar-
ize the orbital electrons of alkali metal atoms, e.g., rubidium, 
through angular-momentum transfer. This polarization is 
then transferred to the nuclear spin system of the gas through 
direct atomic contact. Once mixed with oxygen in the lung, 
the half-life of the hyperpolarised signal is extremely short, 
meaning the fast imaging strategies previously described 
become of vital importance. 
A number of lung-function medical conditions can benefit 
from functional imaging using 3He MRI, as reviewed by 
Fain et al. (23). For example, these images have been used 
for conformal avoidance of lung tissue that is the most active 
in gas exchange, as shown by 3He scans. Figure 1 shows 
such a high-activity region of 3He uptake in orange (right) 
fused to an MRI proton density scan image (left). The orange 
region could then potentially be set as a threshold level, then 
contoured for conformal avoidance during the radiotherapy 
treatment planning process (24). Xenon has the added advan-
tage that its transport into the lung tissue can be detected as a 
chemical shift change with MRSI.
Hyperpolarization also has a role to play in 13C spectros-
copy in the study of tumor metabolism, although this still 
remains a research tool. Its low natural abundance means a 
13C-labeled tracer can be introduced into the body with little 
baseline contamination. Its low sensitivity can be increased 
dramatically with techniques such as dynamic nuclear 
polarization (DNP) and parahydrogen induced polariza-
tion (PHIP) (25, 26). Unlike PET tracers, which are mainly 
analogues of metabolites, 13C tracers undergo metabolic 
changes and can be studied as they alter the appearance of 
the MR spectrum.
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Site-specific Use of MRI in Radiotherapy 
Treatment Planning
This section reviews clinical trials of sites for which vari-
ous MRI sequences and analysis methods have been useful 
in cancer management. The sites selected for review cover 
brain, head and neck, breast, lung, prostate and cervix, and 
are not intended to be exhaustive.
Brain
Owing to its small size and central location within the mag-
net, the brain is one of the easiest organs to image well. 
MRI is well established as the superior imaging modality 
for diagnostic purposes when assessing the brain. In the 
brain, MRI often provides better visualization of tumor 
and normal tissue than CT, and hence the target volume for 
high-precision intracranial radiotherapy is commonly delin-
eated directly on MRI studies (Figure 2). It can be imaged 
in standard diagnostic RF coils usually in the treatment 
position, and its registration to CT is trivial even with dif-
ferences in position. 
The brain was the first site where MRI was routinely used 
in treatment planning. Routine clinical use of MRI in the 
 treatment-planning process of fractionated radiotherapy (RT), 
Figure 2: CT (left) co-registered with a T1-3D-SPGR MRI image set (right). The difference in tumor visualization can be clearly appreciated. 
Figure 1: 3He polarization image showing polarized MR helium 3 diffusion scan (right) fused on a proton-density-weighted MR scan (left). These active 
zones would be the regions of conformal avoidance, defined as low-dose objectives during the radiotherapy treatment planning process.
6 Metcalfe et al.
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fractionated stereotactic radiotherapy (FSRT), stereotactic 
radiosurgery (SRS) and functional radiosurgery (FSRS) has 
been found to be a useful tool in brain tumors.
The treatment target for a patient having a high-grade 
glioma can be determined from both a contrast-enhanced 
T1-weighted high-resolution 3D spoiled-gradient (SPGR) 
image as well as either a standard T2 MR image (27) 
or a fast fluid-attenuated inversion recovery (FLAIR) 
image (28). The T1-weighted high-resolution 3D SPGR is 
used to define the gross visible disease, which is the region 
of the blood-brain barrier breakdown, while the clini-
cal target volume is defined using the T2-weighted image 
series on which the extent of the oedema thought to harbor 
microscopic disease is delineated. On the other hand, for 
benign lesions as well as brain metastases that do not 
invade the normal brain parenchyma, a contrast-enhanced 
T1-weighted 3D SPGR is sufficient for target definition in 
FSRT and SRS (29).
In the treatment of arteriovenous malformations (AVMs), 
magnetic resonance angiography (MRA) is employed for 
the definition of the nidus, which most of the time cannot be 
clearly appreciated on T1-weighted MR images (30). More-
over, in the treatment of trigeminal neuralgia using functional 
stereotactic radiosurgery, 3D fast imaging employing steady-
state acquisition (FIESTA) MRI is employed for visualiza-
tion and targeting of the involved trigeminal nerve 4 mm 
from the root entry zone. Since this imaging technique has a 
significant T2-weighting, the cerebral spinal fluid around the 
brain stem luminates while normal brain and cranial nerves 
appear almost black. This allows delineation of the involved 
trigeminal nerve root as it emanates from the brainstem (31) 
(Figure 3). 
To explore the potential to reliably compare intra- and post-
treatment images with pre-treatment images on a voxel-
by-voxel basis, i.e. using voxel-based functional diffusion 
maps at various time points to predict the response of 
brain metastases to whole-brain radiotherapy, a diffusion-
mapping technique has been developed at the University 
of Wisconsin that allows the reliable comparison of intra- 
and post- treatment images with pre-treatment images on a 
voxel-by-voxel basis (32, 33). 
An example for one patient is shown in Figure 4; green 
points on the graph indicate no change in ADC for a voxel 
from the baseline to the assessment time point, red points 
indicate that the ADC has increased at the assessment 
time point as compared to the baseline and blue points 
indicate that the ADC has decreased from the baseline. An 
increase in ADC (red points) in a voxel indicates increased 
diffusion distance of the water molecules, and hence a 
decrease in cell density, which could indicate that the vol-
ume is responding to therapy. In the same way, no change in 
ADC (green points) could indicate no response to therapy, 
and a decrease in ADC (blue points) indicates a decreased 
diffusion distance of water molecules, and hence an increase 
in cell density, which could indicate a proliferating volume 
of cells during therapy. 
Another brain technique can be used to adopt a conformal 
avoidance strategy. Functional MRI (fMRI) has been incor-
porated into the TPS to consider defining various functional 
organs at risk (fOAR). Work has also looked at the robust-
ness of this technique in terms of recommending planning 
margins of uncertainty (11). The benefits of including such 
information remain to be proven, but results show that sev-
eral primary functional areas can be included in the planning 
prescription without any adverse changes to the planning tar-
get volume (PTV) coverage (12, 34).
In the setting of brain metastases, investigation on the util-
ity of DW-MRI for assessing response to therapy has been 
limited. Goldman et al. have studied diffusion-weighted MRI 
in 15 patients who underwent gamma-knife radiosurgery for 
brain metastases, and demonstrated the potential for early 
changes in mean ADC to predict therapeutic response (35). 
However, their assessment of changes in mean ADC was 
obtained by averaging over an entire metastatic lesion, not by 
using a voxel-by-voxel approach. One potential disadvantage 
of mean ADC is that different areas of tumor with increas-
ing and decreasing changes in diffusion could cancel out, 
such that there would be no observed change in overall mean 
ADC, thus decreasing sensitivity. 
Some MRS data can be incorporated into TPS. Some degree 
of expertise is required in incorporation into planning as use 
of this data is still in its infancy (36, 37)
Figure 3: Visualization of the right trigeminal nerve root using FIESTA 
MR imaging. The arrow points to the right trigeminal nerve root.
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Head and Neck
Historically, the sensitivity of FDG PET was generally 
reported as higher than conventional MRI scans for detecting 
lymphogenic metastesis in head and neck cancer patients. For 
example, Braams et al. (38) reported for FDG PET a sensiti-
vity of 91% and specificity of 88%. In contrast, a sensitivity 
of 36% and a specificity of 94% were calculated for MRI 
using T1- and T2-weighted scans. 
However, with the advent of specialised RF coils for imag-
ing in treatment shells, the use of advanced signal-hungry 
MRI sequences has improved markedly. With specialised 
RF coils patients can also undergo MRI in the treatment 
position, improving the accuracy of any image registration. 
 Figure 5 shows a typical treatment coil for head and neck 
MRI scanning. 
Vandecaveye et al. (15) scanned a 26-patient cohort with per-
sistent or recurrent head and neck squamous cell carcinoma 
(HNSCC). Compared with histopathologic findings, they 
showed a sensitivity and specificity of around 95% using 
ADC analysis. In comparison T1- and T2-weighted MRI 
scans of b0 (s/mm2) images gave a specificity and sensitivity 
Figure 4: MR images at various stages of radiotherapy: (A) before radiotherapy, (B) mid-treatment and (C) post-treatment. The graphs in B and C show the 
voxel-by-voxel ADC values changing as determined during ADC image analysis on MRI. Green points on the graph indicate no change in ADC for a voxel 
from the baseline to the assessment time point, while red points indicate that the ADC in a voxel has increased compared to the baseline, and blue points indi-
cate that it has decreased compared to the baseline.
Figure 5: Photograph showing the set-up for head & neck planning on a wide-bore MRI scanner. A flat tabletop is used in conjunction with the standard 
thermoplastic immobilization shell. Two dedicated RF surface-coil arrays are placed laterally around the shell to enable high-quality imaging in the treatment 
position.
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of approximately 65%, while b1000 images scored a sensitiv-
ity and specificity of about 72%. When compared with com-
puted tomography, TSE-MRI and FDG-PET, the DW-MRI 
sequence analysis yielded the highest sensitivity and specific-
ity with fewer false-positive results in persistent primary site 
abnormalities and in persistent adenopathies, and aided in the 
detection of nodal metastases that were indicated as smaller 
than 1cm diameter. 
There can be advantages in registering and overlaying FDG 
PET images with MRI or CT contours. Nishioka et al. (39) 
showed that the PET scans could be used to confirm whether 
parotid sparing was appropriate by analysing uptake. The 
PET also confirmed that the total number of positive nodes 
in the 21 patients was increased from 28 by physical exami-
nation coupled with CT/MRI to 39 by the image fusion of 
the PET scans with the MRI/CT. The recent introduction of 
combined PET-MRI gantries represent a new exciting area 
of clinical research into analysing the potential advantages of 
combining these imaging data sets, which will have similar 
acquisition time stamps.
Breast 
Breast abnormalities are visible on MRI using both non- 
contrast and contrast-enhanced MRI scans. MRI has been 
shown to have greater sensitivity than mammography for 
assessment of extent of breast cancer under certain clinical 
conditions (40-48), making MRI a potentially interesting tool 
in the appropriate planning of radiotherapy. 
The purpose of standard post-operative tangential radio-
therapy following wide local excision for early breast can-
cer is to treat the remaining breast volume. However, the 
breast volume is poorly defined by CT (49), and attempts are 
often made to supplement identification of breast tissue by 
palpation and delineating on the patient with radio-opaque 
catheters when undergoing CT scanning. Giezen et al. (50) 
performed an exploratory study of MRI versus CT for delin-
eation of breast volume for the purpose of radiotherapy 
planning. In a small study of 15 patients and four volume 
delineators, it was observed that MRI detected breast glandu-
lar tissue beyond that identified by CT scanning, especially 
in the cranial direction, and that this tissue may be conven-
tionally missed geographically if CT planning is relied on 
to delineate volume. The clinical uncertainty is whether this 
“missed” tissue is seen in a larger cohort of patients and 
observers. The current very good local control rates for breast 
conservation radiotherapy in general do pose the question of 
whether these differences in volume make any difference to 
clinical outcome. Recurrence rates are still significant, espe-
cially in younger patients (51) who have denser breasts, and 
this may be a cohort that benefit most from better volume 
delineation. Their findings therefore warrant further exami-
nation. Figure 6 gives an example of a typical breast image 
taken of a patient lying prone in breast coils. 
One difficulty for MRI planning in the breast is the 
 contradictory patient set-ups: treatment is performed in the 
supine position, whereas optimum imaging is performed with 
the patient lying prone and the breasts suspended in separate 
wells of the RF coil. Although MRI of sufficient quality can 
be obtained in the supine position using a body coil array, 
the breast tissue is then positioned further from the isocenter, 
causing issues with geometrical accuracy (52).
An emerging trend is to treat some patients with favourable 
histology with partial breast radiotherapy directed to the site 
of the surgery only. Clinical studies are currently underway. 
Kirby et al. (53) assessed breast-cancer patients positioned 
Figure 6: MR image of breast showing irregularities (anatomical right breast). Most breast images are obtained using breast surface coils to reduce 
the  signal-to-noise ratio, and the patient is usually positioned prone in the coils. This image is courtesy of the Aroura web site (www.Aroura.com).
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prone to determine the value of MRI and CT for planning 
partial breast irradiation (PBI) to the tumor bed (TB). They 
found that TB volumes delineated using fused MR and CT/
clip data were discordant to those delineated using CT/clips 
alone. However, resulting clinical and planning-target vol-
umes were sufficiently concordant to ensure adequate cov-
erage of the target volume using the CT-based tangential 
treatment fields in 26 of 30 cases, suggesting that the use of 
MRI for most cases did not lead to a substantial change in 
treatment volume. Two of the 30 cases showed inadequate 
coverage due to discordance between volumes, both infe-
riorly. Another two of the 30 cases showed that inadequate 
coverage was related to the target volumes being located at 
the peripheries of breast tissue, where coverage is difficult 
due to the complex 3D shape of breast tissue. This study sug-
gests that MRI may only have a limited role to play in delin-
eation of the TB post-operatively when CT data with clips 
defining the TB is available.
However, there may be a role in the future for defining the 
TB pre-operatively using MRI as the imaging modality of 
choice. The study reported by Schmitz et al. (54) compares 
breast MRI with pathology to assess treatment margins in 62 
patients. While the MRI-estimated GTV showed close con-
cordance with the pathologic samples, these samples also 
showed significant spread of occult pathology. The findings 
report that for MRI-guided minimally invasive therapy, typi-
cal treatment margins of 10 mm around the MRI-GTV may 
not incorporate occult disease in 52% of patients. When sur-
gery achieves a 10 mm tumor-free margin around the MRI-
GTV, radiotherapy to the TB may require clinical target 
volume margins of greater than 10 mm in up to 25% of the 
patients. The outcome from breast-conservation studies does 
not suggest such a high recurrence rate as might be predicted 
by these figures, but may perhaps identify patients who might 
be at greater risk of recurrence. Correlation of tumor extent 
with breast recurrence rates will be required.
Ultra small particles of iron oxides can act as a negative con-
trast agent and are taken up by normal tissue on T2* weighted 
sequences. Their sensitivity and specificity for detecting 
nodal metastases is high (55). These allow detection of 
micrometastases in the nodes as small as 2 mm in diameter. 
New promising agents such as ferumoxytol are under inves-
tigations for FDA approval.
Lung
CT scans with the addition of FDG PET is the standard of 
care for diagnosis of lung cancer; however, there is poor dis-
tinction between structures with similar electron densities, 
making it difficult to differentiate lung cancers from sur-
rounding lung collapse, consolidation or effusion. MRI can 
enable differentiation of these situations through improved 
soft-tissue contrast. MRI scans can be undertaken in a similar 
position to that used for radiotherapy treatment.
Figure 7 shows a T2-weighted single-shot fast-spin echo 
(SSFSE) image of a small-cell lung cancer. There is excellent 
differentiation between mediastinum and tumor mass, while 
the boundary between tumor and consolidation is less clear. 
Of particular interest for defining radiotherapy treatment 
volumes for lung cancer is the ability to accurately deter-
mine lung-cancer motion. MRI is becoming an increasingly 
attractive modality to image this motion. Parallel imaging 
Figure 7: Axial, coronal and sagittal plane of a T2-weighted single-shot 
fast-spin echo image of a small-cell lung cancer for a 64-year-old male with 
T4 N2 M0 disease. There is excellent differentiation between the mediasti-
num and tumor mass, although the boundary between the tumor and the con-
solidation is unclear. (Images done on 1.5T GE scanner, with inspiration 
breath-hold.) 
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techniques improve both spatial and temporal resolution. 
There are two particular sequences useful in imaging motion: 
fast low-angle shot (FLASH) sequences and true fast imag-
ing with steady-state precession (TrueFISP) sequences. 
Plathow et al. (56) investigated these two imaging sequences 
to quantify tumor mobility in 20 patients with Stage I non 
small cell lung cancer (NSCLC). Both techniques showed 
regular, synchronous diaphragm and chest-wall motion of 
diagnostic quality. The TrueFISP sequence acquired three 
images per second, allowing for continuous recording during 
the respiratory cycle, and correlated well with the FLASH 
sequences, which acquired 10 images per second. There were 
no significant differences in measurement of tumor mobility 
between the techniques; however, the signal-to-noise ratio 
was superior for TrueFISP. 
Other sequences used to image motion include a multi-
slice breath-hold steady-state free-precession sequence and 
dynamic 3D free-breathing fast-field echo planar imaging 
(FFE-EPI). Blackall et al. (57) used these sequences to evalu-
ate 3D geometric errors associated with respiratory motion 
variability in 10 volunteers and five lung-cancer patients. The 
protocols were optimized for each participant by adjusting 
the voxel size, to obtain coverage of the entire lung at the 
highest possible resolution while maintaining an acceptably 
short acquisition time. The participants were coached to help 
them regulate breathing. Images were acquired throughout 
the respiratory cycle and registered to demonstrate motion 
using different models. Respiratory-motion models based on 
rapidly acquired free-breathing MRI data showed reasonably 
good levels of inter-cycle reproducibility, with mean errors 
at the lung surface in the range of 1.7 to 3.9 mm for healthy 
volunteers, and 2.8 to 3.3 mm for lung-cancer patients. Inter- 
and intra-cycle variability were less during exhalation. 
Dynamic MRI can thus be used to define a patient-specific 
ITV for planning of lung cancers for radiotherapy. It allows 
the entire lung volume to be imaged fast enough to analyse 
true motion and deformation over the breathing cycle, while 
the patient breathes freely, as occurs during radiotherapy 
treatment. MRI studies using TrueFISP sequences have 
shown that lower-lobe tumors move more than upper- or 
middle-lobe tumors, and that the movement of tumor-bearing 
lung is reduced compared to normal lungs (12, 58) . The lat-
ter is also dependent on tumor diameter, with less movement 
seen in larger tumors (58). However, dynamic MRI of the 
lung is prone to artefact, which affects registration accuracy 
for the purposes of radiotherapy planning.
Dynamic MRI imaging of lung cancers can be used for prob-
ability density function (PDF), planning whereby the dose 
distribution of radiotherapy is modulated by the probabil-
ity that the target occupies that location. In a study using 
17 healthy volunteers and lung-cancer patients, Cai et al. (59) 
developed a technique to measure this using TrueFISP 
sequence. Improvement in PDF reproducibility was observed 
with increased imaging duration and a greater number of 
sampled breathing cycles. Two patient-specific imaging 
acquisitions were recommended to establish the reproduc-
ibility of the PDF if PDF-based treatment planning was being 
considered. 
The current standard of 4DCT is not as accurate in deter-
mining the tumor-motion PDF. It has lower temporal 
resolution, particularly in detecting craniocaudal motion. 
The tumor-motion trajectory is measured from segments 
of numerous breathing cycles rather than a single breath-
ing cycle. To take true respiratory motion into account for 
radiotherapy planning and treatment the entire organ needs 
to be imaged at high speed while the patient breathes nor-
mally. This is not possible with 4DCT. Variability in respi-
ratory motion from one cycle to the next can be magnified 
in 4DCT images, leading to artefacts. It cannot image the 
statistically needed number of complete breathing cycles for 
a reproducible PDF. 
There have been no definitive contouring studies compar-
ing the delineation of lung cancer on MRI to CT or PET-
CT scans. As a diagnostic tool in differentiating benign from 
malignant nodules, techniques such as DWI have shown sim-
ilar accuracy to PET scans (60). DCE-MRI has shown some 
promise in differentiating between subtypes of lung cancer in 
inoperable cases (61). This may have an impact on determi-
nation of CTV margins and type of chemotherapy delivery 
in cases where histological subtype has not been determined 
by biopsy. 
The use of MRI to avoid normal tissues in lung-cancer 
radiotherapy planning is an emerging area of research. This 
is possible with the use of inert hyperpolarized helium-3 
gas, which is inhaled to demonstrate regional lung function 
by selective display of ventilated air spaces. Non-ventilated 
regions show up as signal voids. Bates et al. (62) contoured 
functional lung based on helium MRI on seven patients 
with Stage III NSCLC (14). Two IMRT plans were created: 
the first to minimise total lung volume receiving >20 Gy 
(V20) and the second to minimise functional lung volume 
receiving >20 Gy (fV20). In all patients, the addition of 
functional information reduced both V20 and fV20 without 
compromising target coverage. The median reduction in 
V20 was 1.5% and fV20 2.7%; however, mean lung dose 
was not significantly different. Larger reductions were seen 
if the non-functional lung was 25% of total lung volume. 
Similarly, Ireland et al. (63) observed a median reduction 
of 1.6% in V20 and 3.1% in fV20 in six plans. The greatest 
benefit was seen if functional lung lay in the path of the 
beam and could therefore be spared by alternative beam 
arrangements. 
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MRI scans can be used to evaluate changes in lung tumors 
and normal tissue response during a course of radiother-
apy. Yankelevitz et al. (64) performed 0.6T MRI scans 
before, during and after radiotherapy in 10 patients. After 
20 Gy tumors decreased by 38%, and after 40 Gy by 64%. 
All patients showed increased signal intensity in normal 
lung tissue during radiotherapy but without clinical evi-
dence of radiation pneumonitis. This increased up to six 
months after radiotherapy before decreasing. Other authors 
have noted changes in tumor vascular permeability on 
DCE-MRI during treatment, reflecting changes in micro-
vascular structure (65). MRI has the potential to allow 
adaptive radiotherapy planning in response to changes dur-
ing treatment. 
Finally, MRI may be used as a prognostic tool for treat-
ment outcomes. Ohno et al. (66) performed post-treatment 
DCE-MRI scans in 114 evaluated patients who had chemo-
radiotherapy for Stage III NSCLC. A breath-hold technique 
at end-inspiration was used. Patients were divided into 
two groups for analysis: those with local control and those 
with local failure. Signal-intensity time curves of the tumor 
and normal lung were created and evaluated. Survival was 
compared above and below an adopted threshold value for 
dynamic MRI index. An 11-month difference in survival was 
noted between the two groups. However this has not been 
compared to other imaging such as PET scans. 
Prostate 
The use of MRI for diagnosis of prostate cancer is not cur-
rently standard; however, MRI is recognised as a superior 
imaging modality in defining the prostate volume accurately, 
and, with advanced techniques such as MRSI, has the ability 
to distinguish between the cancer volume and normal pros-
tate tissues.
Prostate scans may be acquired in the treatment position 
using a flat tabletop and a posterior RF coil placed under-
neath it without too much loss of quality (67). A support over 
the body can be used to avoid compression from the anterior 
RF coil if required. Any residual distortion at the skin sur-
face can be largely ignored or a smaller FOV acquired and 
matched to sufficient bony anatomy in the CT.
A clear indication for MRI is in cases of bilateral hip replace-
ment; Rosewall et al. (68) showed that smaller prostate vol-
umes were delineated on the MRI compared to CT, which is 
adversely effected by high Z artefacts. In contrast, there is no 
effect from the susceptibility artefacts on the MRI, which are 
confined to within the prostheses.
For gold-seed localization as used in image guidance for intact 
prostate radiotherapy, the MRI exam sequence may include a 
gradient echo-based sequence that improves the visualization 
of the markers by virtue of susceptibility artefacts.
Khoo et al. (69) undertook a five-patient cohort study to com-
pare contour segmentation of structures in the prostate region. 
Using a subjective scoring system, they concluded that MRI 
was superior to CT when observers were segmenting the 
prostate apex and rectum. The FLASH 3D sequence showed 
the best images, as no volume averaging was involved with 
this sequence.
Haider et al. (70) studied 33 prostate patients with suspected 
relapse after external beam radiotherapy. They compared 
T2-weighted with dynamic contrast enhanced (DCE) MRI 
scans, concluding that DCE-MRI performed better than 
T2-weighted imaging in the detection and localization of 
prostate cancer in the peripheral zone after EBRT. This find-
ing may be helpful in the planning of salvage treatments.
McLaughlin et al. (71) explored the premise that vessels 
involved in erectile function – the corpus cavernosum (CC) 
and the internal pudental artery (IPA) – may be affected by 
radiation, based on proven radiation effects to other vascula-
ture structures in the body. They studied 25 patients under-
going radiotherapy, 10 external beam and 15 brachytherapy 
patients. MRI T2 sequences (axial, coronal and sagittal) were 
obtained with a pelvic coil. Of these patients, 10 were entered 
on a vessel-sparing protocol and underwent treatment- 
planning CT. In addition, a non-contrast MRI angiogram 
was obtained to define the IPA. The proximal CC was clearly 
defined on axial and coronal T2 MRI. Hence they showed the 
potential of MRI to visualize the prostate and erectile struc-
tures. They registered the MRI data sets by mutual informa-
tion and created radiotherapy treatment plans that allowed 
dose limitation to the critical erectile tissues (the CC and 
IPA) without compromising target coverage. While these 
structures are visible with MR angiography, the researchers 
suggested that coronal images using conventional MRI T2 
sequences provide sufficient detail of the outline and posi-
tion of these vessels for conformal avoidance in radiotherapy. 
They predicted that it erectile vessel-sparing radiotherapy 
may have as favourable an impact on sexual potency after 
radiation as nerve-sparing prostatectomy.
McLaughlin et al. (71) also includes useful data on dis-
tances from the prostate apex to the penile bulb. While the 
mean range in their sample was 1.45 cm, they observed 
ranges in distance between these structures of between 
0.7 and 2.1 cm. This suggests that the standard distance 
of 1.5 cm used with CT images may sometimes over- or 
 underestimate distance from the apex to the vascular struc-
tures. They suggested that the use of this rule would have 
underestimated the distance in one half of their patient 
cohort, potentially leading to marginal miss. The prostate 
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volume would have been overestimated in the other half of 
their patients, limiting the degree to which erectile tissue 
was spared in these patients. 
The argument for MR images in combination with CT for 
prostate radiotherapy treatment planning is compelling. 
However, issues remain for some of the functional tech-
niques previously described to be used in treating the pros-
tate. The requirement of sufficient signal-to-noise in MRSI 
for example, usually demands the use of endorectal receiver 
coils, which distort the prostate compared to its position on 
CT acquisition. Remedies to this include higher field strength 
and/or less invasive coil designs.
The evolution of multiparametric combinations of MRI 
sequence information, for example combining information 
from T2w, DCE, DW 1/2 MRS is rapidly growing in pros-
tate cancer detection and mapping. It increases the power 
of MRI over each single sequence. This may be of value in 
the context of radiotherapy-planning. Moreover, preliminary 
data on hybrid PET/MRI suggests that Choline/ADC maps 
could more accurately predict tumor staging and mapping. 
Multimodal imaging or multiparametric MRI could play a 
major role in the context of focal therapies or focal dose 
escalation (72). 
Blood oxygenation can be monitored non invasively with 
MRI potentially providing information regarding tumour 
hypoxia. Blood oxygen level dependent (BOLD) sequence 
studies have shown a direct correlation between measure-
ments of oxygen using an Eppendorf electrode and R2* 
relaxation time. These parameter maps can highlight areas 
that are likely to be radioresistant and requiring a boost in 
dose (73). 
Cervix
MRI is well established as the optimum imaging modality for 
cervical-cancer diagnosis in comparison to CT and clinical 
examination (74, 75). Challenges in determining the extent 
of cervical cancer are in detecting stromal invasion (74, 75) 
and establishing lymph-node status. Detection of lymph-
node invasion is currently most accurate with FDG-PET 
imaging. However, the accuracy of MRI has been improved 
with ultrasmall superparamagnetic iron oxide particles that 
are lymph-node specific contrast agents (76); future research 
may improve this further.
Use of MRI for radiotherapy treatment planning, moni-
toring of tumor response over the course of treatment and 
assessment of relapse following treatment has been inves-
tigated for over a decade. MRI is considered the imaging 
modality of choice for radiotherapy contouring, with signifi-
cant improvement in contrast between the target volume and 
normal tissues (77-79). MRI has been the imaging modality 
of choice for radiotherapy delineation for a number of clini-
cal trials (79).
MRI sequences for radiotherapy delineation purposes are 
usually T2-weighted (80-83). The choice of coil has varied 
throughout the literature, with details often not provided; 
however, when described, generally in more recent inves-
tigations (84), it was usually a body coil with phased array 
coils. Similarly, patient positioning is often not detailed in 
the literature; however, a number of studies have achieved 
MRI scanning positions that mimic treatment position, 
including a flat couch top (82, 83, 85). The significance of 
treatment positioning in cervix MRI scanning for radiother-
apy has not been assessed. The field of view (FOV) used 
for cervix MRI for radiotherapy purposes also varied, rang-
ing from covering only the target and surrounding nearby 
regions (83) to encompassing the majority of the patient 
volume (84).
A number of other MRI sequences have been considered for 
the purpose of radiotherapy target volume definition and treat-
ment response assessment, including T1-weighted sequences 
with and without fat suppression (81, 82, 86). Recently the 
use of diffusion-weighted imaging and ADC values has been 
investigated as a potential tool for predicting and monitoring 
treatment response (84, 87). Although use of ADC values for 
determining patients likely to respond well to radiotherapy 
has not yet been well established, early work is promising 
and warrants further investigation.
Following guidelines published in 2006 (88), MRI is being 
increasingly used in image-guided brachytherapy (IGBT) of 
the cervix. MR-compatible applicators made from materials 
such as titanium or plastic can be imaged safely in vivo with 
little susceptibility to artefacts using fast spin-echo based 
protocols. Work is currently being carried out to improve the 
visualization of these applicators on MRI using short or even 
ultrashort TE sequences.
Discussion
Use of MRI for radiotherapy treatment planning is well 
established for many treatment sites such as brain and head 
and neck, with its use in many others under investigation. 
There is a growing body of literature considering the use of 
MRI for radiotherapy treatment planning. As noted in sec-
tion one of the results, a large and growing number of MRI 
sequences have been considered for the purposes of radio-
therapy treatment planning. T1 and T2 scans are commonly 
used in many treatment sites. The use of DWI is showing 
promise in a number of clinical areas for establishing nodal 
involvement, and thus target volume, as well as for consider-
ing response assessment.
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MRI has a proven track record in brain function studies. MR 
sequences in the brain aid in the diagnosis and staging of 
brain tumors (e.g., glioma). Early studies show a correlation 
between tumor activity and DW images using fDM analysis 
methods. In some non-malignant diagnosis such as AVM and 
the trigeminal nerve in Neuralgia patients, specialized MR 
techniques (e.g., MR angiography) have been used to provide 
exquisite targeting information for stereotactic radiosurgery 
applications.
MRI has been used in combination with PET scan and CT 
in head and neck treatment. Standard MRI techniques show 
the soft-tissue boundaries in this region, while PET has 
been effectively used to track regions of high activity that 
have high specificity to potential nodal involvement. DW-
MRI using ADC methods shows promise in differentiating 
regions of tumor recurrence. There is a very high correlation 
in specificity and sensitivity when compared with pathologi-
cal samples.
MRI has shown the potential to provide a more accurate 
picture of the GTV, compared with current methods such as 
CT. When combined with pathological analysis, surprisingly 
large treatment margins are sometimes required. One study 
has found that when surgery achieves a 10 mm tumor-free 
margin around the MRI-GTV, radiotherapy to the tumor bed 
may require clinical target-volume margins of greater than 
10 mm in up to 25% of patients (54).
The future use of MRI may have an impact on discerning 
which clinical stages are suitable for partial breast irradiation 
techniques. The use of MR seems to indicate more regions 
of abnormality post-surgery and prior to other interventions. 
This may indeed have a major impact on cancer manage-
ment into the future. It is not clear yet that there is an MRI 
technique that can discern breast tissue from other tissue. 
But it does seem clear that breast anomalies in and around 
the excised tumor bed are highlighted with subsequent MRI 
imaging.
MRI has huge potential in radiotherapy treatment of lung 
cancer. It has a role in diagnosis, tumor delineation, measure-
ment of motion and identifying functional normal tissues to 
avoid. It can also be used during radiotherapy to allow poten-
tial treatment adaptation in response to changes occurring in 
the lung tumor and surrounding normal tissues. Its superior 
soft-tissue contrast and lack of ionizing radiation compared 
to CT makes it an attractive imaging modality, particularly 
for repeated imaging. However, there are still hurdles to be 
overcome, a major one being the lack of electron-density data 
for radiotherapy planning. 
Anatomical structures within the prostate such as the apex 
and the seminal vesicles are more clearly visible on MRI than 
CT. This can lead to more accurate and precise outlining of 
the GTV using the MRI images than CT alone. T2 and DCE 
MRI imaging techniques aid in diagnosing sites of potential 
relapse. Vascular structures such as the corpus cavernosum 
internal pudental artery (IPA) that are involved in erec-
tile function can be visualized using MR angiography and 
conventional coronal MRI imaging methods. These may be 
potential sites for conformal avoidance in future radiotherapy 
treatment regimens. 
Use of MRI for the purposes of radiotherapy treatment plan-
ning, monitoring of tumor response over the course of treat-
ment and assessment of relapse following treatment has 
been investigated for over a decade. Use of MRI for the pur-
poses of radiotherapy contouring is considered the imaging 
modality of choice, with significant improvement in contrast 
between the target volume and normal tissues. MRI has been 
the imaging modality of choice for radiation therapy delin-
eation for a number of clinical trials involving the cervix 
cancer-treatment site.
The debate over what field strength is optimum for MRI 
simulation remains inconclusive. Dedicated MR scanners 
for RT planning are presently being installed at both 1.5 and 
3.0 Tesla. The utilization of MRI will certainly have a bear-
ing on this; the soft-tissue anatomical delineation benefits are 
adequately provided for at 1.5 Tesla. However, the increase 
in signal-to-noise, which doubles by going to 3.0 Tesla, is 
important in signal hungry applications. This may be par-
ticularly useful for the functional techniques and in follow-
ing treatment response. Generally imaging in the body is 
made more difficult at higher field strength due to increases 
in several artefacts and dielectric effects. Some of the RF 
homogeneity issues of the latter are now solved with the ven-
dors providing dual transmit technology. Over the proceed-
ing years those centres that have elected to install 3.0 Tesla 
should be able to provide data to make the optimal choice 
clearer.
Use of MRI for radiotherapy treatment planning is com-
monly undertaken to supplement CT imaging; this is still the 
standard of care. Radiotherapy treatment planning with MRI 
alone presents two challenges: the determination of electron 
density as required for accurate radiotherapy dose calcula-
tions; and geometrical accuracy. MRIs do not inherently 
provide any information on electron density and, particularly 
towards edge of the bore, may show significant distortion. A 
number of approaches have been undertaken to address these 
issues, with a methodologies being developed for radiother-
apy treatment planning using MRI alone. 
With the introduction of MRI-linear accelerators and the 
potential for real-time adaptive radiotherapy, geomet-
ric accuracy and electron-density accuracy will require 
14 Metcalfe et al.
Technology in Cancer Research & Treatment 2013 April 24. Epub ahead of print
further investigation as treatment margins are reduced 
and the impact of geometry and dose-calculation errors is 
increased. The (ViewRay™) MRI-Cobalt machine is likely 
to give us the first window into how successful MR will be 
as an online image guidance modality. Sagittal images can 
be acquired using a fast 4 frame per second planar treat-
ment scan that is based on the TRUFI (true fast imaging 
with steady state precession) sequence (89) known to pro-
vide the best SNR at very high speed among the existing 
fast imaging sequences. TRUFI is a type of fast gradient 
echo sequence (90).
Currently there are two working MRI-Linac prototypes. These 
include a modified 6 MV Elekta accelerator merged with a 
modified 1.5 T Philips Achieva MRI system with the linac 
beam transverse to the magnetic field (4). The transverse field 
approach  results in numerous dose perturbation effects includ-
ing the electron return effect, lateral dose shifting, cavity under 
and overdosing (91-93), and potentially large entry and exit 
skin dose increases (94, 95). These effects are reduced at low 
magnetic fields and multiple beam angles reduce the impact 
of skin dose. The other prototype includes a 6 MV accelerator 
merged with a biplanar, low field MRI (3, 96), whereby the 
linac and magnets can both rotate, hence enabling the linac 
beam to be in line with the magnetic field. This potentially 
also involves enhanced skin dose (5) from focused contamina-
tion. However clever design of the magnet may reduce this 
effect (97).
Conclusions
MRI has a proven role in stereotactic targeting in the brain; 
the potential for enhanced application of MRI in radiotherapy 
treatment planning to other cancer treatment sites in the body 
represents an exciting area of further research that deserves 
exploration. In the future the increased availability of dedi-
cated scanners combined with the lack of ionising radiation 
make treatment planning using MRI alone a realistic and 
desirable prospect. 
Experience has already shown that MR-only planning is 
feasible in brain (98), prostate (99) and several other areas 
(100). Developments in imaging sequences and bone-tissue 
segmentation combined with the production of good-quality 
pseudo-DRRs for patient set-up are all being investigated to 
further enhance this work. The logical progression of this 
MRI-guided strategy is the clinical prototyping of hybrid 
MRI-linear accelerator systems that will provide the ultimate 
in adaptive radiotherapy.
We hope this description of various MRI techniques applied 
to clinical trials indicates a pathway forward for enhanced 
use of MRI in TPS, leading perhaps to improved therapeu-
tic ratio for patients and improved patient management in 
general. The breadth and scope of MRI sequences and analy-
sis techniques is such that they can be considered analogous 
to opening a box of chocolates. One is never quite sure what 
is in the box but usually one is surprised by the sweetness of 
the outcome.
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